Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercialize via the F ...

诉讼事件概述 - 德克萨斯州总检察长肯·帕克斯顿对百时美施贵宝和赛诺菲公司提起诉讼 [1] - 诉讼指控制药公司未能披露其抗凝血药物波立维对某些患者群体效果不佳的信息 [1] 涉事公司及产品 - 涉事公司为百时美施贵宝和赛诺菲 [1] - 涉事产品为用于预防血栓的药物波立维 [1]